Everett Harris & Co. CA purchased a new position in Roche Holding AG (OTCMKTS:RHHBY - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,809 shares of the company's stock, valued at approximately $445,000.
A number of other hedge funds have also recently made changes to their positions in the stock. Accent Capital Management LLC purchased a new stake in Roche in the first quarter worth about $35,000. Fulton Bank N.A. raised its holdings in shares of Roche by 2.6% during the 1st quarter. Fulton Bank N.A. now owns 12,620 shares of the company's stock worth $518,000 after acquiring an additional 314 shares during the period. GAMMA Investing LLC raised its holdings in shares of Roche by 59.5% during the 1st quarter. GAMMA Investing LLC now owns 12,850 shares of the company's stock worth $529,000 after acquiring an additional 4,794 shares during the period. Confluence Investment Management LLC raised its holdings in shares of Roche by 3.6% during the 1st quarter. Confluence Investment Management LLC now owns 14,491 shares of the company's stock worth $596,000 after acquiring an additional 510 shares during the period. Finally, PNC Financial Services Group Inc. raised its holdings in shares of Roche by 2.0% during the 1st quarter. PNC Financial Services Group Inc. now owns 16,234 shares of the company's stock worth $668,000 after acquiring an additional 323 shares during the period.
Roche Trading Up 1.2%
Shares of Roche stock traded up $0.47 during trading hours on Wednesday, reaching $38.59. The stock had a trading volume of 940,787 shares, compared to its average volume of 2,330,295. The firm has a 50 day simple moving average of $40.19 and a two-hundred day simple moving average of $40.26. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.20 and a current ratio of 1.48. Roche Holding AG has a 1 year low of $34.10 and a 1 year high of $44.31.
Analyst Ratings Changes
Several equities analysts have weighed in on the company. Hsbc Global Res downgraded Roche from a "strong-buy" rating to a "hold" rating in a research report on Monday, April 28th. HSBC downgraded Roche from a "buy" rating to a "hold" rating in a research report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy".
Check Out Our Latest Analysis on RHHBY
About Roche
(
Free Report)
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
See Also

Before you consider Roche, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roche wasn't on the list.
While Roche currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.